From: Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
Predictors | PCI mean (min-max) |
---|---|
Basal EGF concentration | 0.005 (0.003–0.008) |
Eosinophils | 0.001 (0.001–0.002) |
Lymphocytes | 0.007 (0.005–0.012) |
Neutrophils | 0.030 (0.019–0.051) |
Platelets | 0.036 (0.023–0.059) |
Monocytes | 0.163 (0.108–0.259) |
NLR | 0.025 (0.016–0.043) |
PLR | 0.004 (0.003–0.008) |
Proportion of CD19+ B cell | 0.053 (0.034–0.087) |
Proportion of CD8+ T cell | 0.087 (0.062–0.127) |
Proportion of CD8 + CD28- T cell | 0.148 (0.098–0.239) |
CD4+/CD8+ ratio | 0.443 (0.324–0.626) |
Proportion of CD4+ T cell | 0.486 (0.353–0.694) |